These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 20452982

  • 1. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
    Pene-Dumitrescu T, Smithgall TE.
    J Biol Chem; 2010 Jul 09; 285(28):21446-57. PubMed ID: 20452982
    [Abstract] [Full Text] [Related]

  • 2. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y, Rahmani M, Pei XY, Dent P, Grant S.
    Blood; 2004 Jul 15; 104(2):509-18. PubMed ID: 15039284
    [Abstract] [Full Text] [Related]

  • 3. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
    Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE.
    Oncogene; 2008 Nov 27; 27(56):7055-69. PubMed ID: 18794796
    [Abstract] [Full Text] [Related]

  • 4. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ.
    Blood; 2008 Apr 01; 111(7):3821-9. PubMed ID: 18235045
    [Abstract] [Full Text] [Related]

  • 5. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M.
    Blood; 2003 Jan 15; 101(2):690-8. PubMed ID: 12509383
    [Abstract] [Full Text] [Related]

  • 6. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 7. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.
    J Natl Cancer Inst; 2008 Jul 02; 100(13):926-39. PubMed ID: 18577747
    [Abstract] [Full Text] [Related]

  • 8. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 02; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 9. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 02; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 10. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

  • 11. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.
    J Biol Chem; 2004 Aug 13; 279(33):34227-39. PubMed ID: 15175350
    [Abstract] [Full Text] [Related]

  • 12. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
    Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O.
    Int J Oncol; 2013 Feb 13; 42(2):419-28. PubMed ID: 23233201
    [Abstract] [Full Text] [Related]

  • 13. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F, Fandi A, Voi M.
    Int J Biochem Cell Biol; 2008 Feb 13; 40(3):334-43. PubMed ID: 18401881
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 16. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK, Rahmani M, Harada H, Dent P, Grant S.
    Blood; 2007 May 01; 109(9):4006-15. PubMed ID: 17218385
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T.
    Int J Cancer; 2008 Jun 01; 122(11):2621-7. PubMed ID: 18338755
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
    Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV.
    Leukemia; 2004 Aug 01; 18(8):1352-6. PubMed ID: 15201856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.